National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meeting
Published Date: 2/2/2026
Notice
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a meeting on June 2, 2026, that’s partly open to the public and partly closed to protect private info about grant applications. Researchers and the public can join the open session online or in person, while the closed session will review important funding decisions. This meeting helps decide who gets money to study arthritis and related diseases, shaping future research and treatments.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Public Open Session and Videocast
You can attend the open part of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council meeting on June 2, 2026, from 9:30 a.m. to 2:00 p.m. in person at NIH Building 31 (31 Center Drive, Bethesda, MD 20892) or watch the videocast at https://videocast.nih.gov/. Registration is not required for the open portion.
Closed Session to Review Grant Applications
On June 2, 2026, from 2:15 p.m. to 4:30 p.m., the council will meet in closed session to review and evaluate grant applications; discussions may disclose confidential trade secrets, patentable material, or personal information and will be closed to protect that information. This closed review is part of deciding who receives research funding for arthritis and related diseases.
On‑site Security and Visitor ID Procedures
If you come to the NIH campus for the meeting, NIH security procedures require visitors to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and state the purpose of their visit; all visitor vehicles will be inspected before being allowed on campus.
Reasonable Accommodations Available
If you need special assistance to attend the open session (for example, sign language interpretation), you should notify the Contact Person in advance so NIH can provide reasonable accommodations for the June 2, 2026 meeting.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2026-01942, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Amended Notice of Meeting
Heads up! The Eunice Kennedy Shriver National Institute of Child Health and Human Development is extending its big May 2026 meeting from one day to two days. This change affects anyone interested in medical rehab research and means more time for important discussions, all happening in Bethesda and open to the public.
Next: 2026-01944, Importer of Controlled Substances Application: Sharp Clinical Services, LLC
Sharp Clinical Services, LLC wants to become an official importer of certain controlled substances, including some Schedule I drugs like Gamma Hydroxybutyric Acid and MDMA. This affects companies involved in drug manufacturing and regulation, who can comment or request a hearing by March 4, 2026. No fees or immediate changes yet, but this step could impact drug supply chains soon.